Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08

Blood 2026 Open access

Read full text
Authors: Jamie E. Flerlage, Angela M. Feraco, Yiwang Zhou, Ying Zheng, Jia Liang, John T. Lucas, Alison M. Friedmann, Howard J. Weinstein, Torunn I. Yock, Barry L. Shulkin, SC Kaste, Lianna J. Marks
+14 more Matthew J Ehrhardt, S Dixon, Scott C. Howard, Pedro de Alarcón, Sandra Luna-Fineman, Amy E. Geddis, Eric Larsen, Karen Marcus, Amy L. Billett, Donaldson Ss, M M Hudson, Monika L. Metzger, M. Krasin, M Link
DOI: 10.1182/blood.2025029535
Cited by: 2
References: 32

Abstract

ABSTRACT: The Pediatric Hodgkin Consortium hypothesized that by increasing chemotherapeutic dose density for Hodgkin lymphoma (HL) they could increase the complete response (CR) rate among patients with favorable-risk HL after 8 weeks of Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide and prednisone) compared with 8 weeks of VAMP (vinblastine, Adriamycin [doxorubicin], methotrexate, and prednisone). This would translate to a decrease in patients who required radiation therapy (RT) to achieve a cure. The HOD08 study was a phase 2 multicenter, investigator-initiated single-arm trial for patients aged ≤21 years with previously untreated stage 1A or 2A HL without mediastinal bulk or extranodal disease extension and

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Lymphadenopathy Diagnosis and Analysis Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
12
Pages
1289–1301
Publication date
13 January 2026
Language
EN